Angiogenesis in Gliomas: Imaging and Experimental Therapeutics

Overview

Journal Brain Pathol

Date 2006 Jan 5

PMID 16389946

Citations 27

Authors

Jean-Pierre Gagner

Meng Law

Ingeborg Fischer

Elizabeth W Newcomb

David Zagzag

Affiliations

Soon will be listed here.

Abstract

Much of the interest in angiogenesis and hypoxia has led to investigating diagnostic imaging methodologies and developing efficacious agents against angiogenesis in gliomas. In many ways, because of the cytostatic effects of these agents on tumor growth and tumor-associated endothelial cells, the effects of therapy are not immediately evident. Hence finding clinically applicable imaging tools and pathologic surrogate markers is an important step in translating glioma biology to therapeutics. There are a variety of strategies in the approach to experimental therapeutics that target the hypoxia-inducible factor pathway, the endogenous antiangiogenic and proangiogenic factors and their receptors, adhesion molecules, matrix proteases and cytokines, and the existing vasculature. We discuss the rationale for antiangiogenesis as a treatment strategy, the preclinical and clinical assessment of antiangiogenic interventions and finally focus on the various treatment strategies, including combining antiangiogenic drugs with radiation and chemotherapy.

Citing Articles

Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments.

De La Torre P, Perez-Lorenzo M, Alcazar-Garrido A, Flores A Molecules. 2020; 25(3).

PMID: 32046010 PMC: 7038177. DOI: 10.3390/molecules25030715.

Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far.

Clavreul A, Pourbaghi-Masouleh M, Roger E, Menei P Int J Nanomedicine. 2019; 14:2497-2513.

PMID: 31040671 PMC: 6461002. DOI: 10.2147/IJN.S194858.

Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.

Brendle C, Hempel J, Schittenhelm J, Skardelly M, Tabatabai G, Bender B Clin Neuroradiol. 2017; 28(3):421-428.

PMID: 28488024 DOI: 10.1007/s00062-017-0590-z.

Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation.

Svolos P, Reddick W, Edwards A, Sykes A, Li Y, Glass J AJNR Am J Neuroradiol. 2017; 38(6):1235-1241.

PMID: 28428205 PMC: 5471144. DOI: 10.3174/ajnr.A5159.

Glioblastoma, hypoxia and autophagy: a survival-prone 'ménage-à-trois'.

Jawhari S, Ratinaud M, Verdier M Cell Death Dis. 2016; 7(10):e2434.

PMID: 27787518 PMC: 5133985. DOI: 10.1038/cddis.2016.318.

References

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

Herschman H . Molecular imaging: looking at problems, seeing solutions. Science. 2003; 302(5645):605-8. DOI: 10.1126/science.1090585. View

Nabeshima K, Shimao Y, Sato S, Kataoka H, Moriyama T, Kawano H . Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study. Histopathology. 1998; 31(5):436-43. DOI: 10.1046/j.1365-2559.1997.3010889.x. View

Law M, Yang S, Babb J, Knopp E, Golfinos J, Zagzag D . Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004; 25(5):746-55. PMC: 7974484. View

Gondi C, Lakka S, Yanamandra N, Olivero W, Dinh D, Gujrati M . Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res. 2004; 64(12):4069-77. DOI: 10.1158/0008-5472.CAN-04-1243. View

Eikesdal H, Bjerkvig R, Raleigh J, Mella O, Dahl O . Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiother Oncol. 2001; 61(3):313-20. DOI: 10.1016/s0167-8140(01)00450-9. View

Larson D, Prados M, Lamborn K, Smith V, Sneed P, Chang S . Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 2002; 54(5):1397-404. DOI: 10.1016/s0360-3016(02)03743-4. View

Kortmann R, Jeremic B, Weller M, Plasswilm L, Bamberg M . Radiochemotherapy of malignant glioma in adults. Clinical experiences. Strahlenther Onkol. 2003; 179(4):219-32. DOI: 10.1007/s00066-003-1027-y. View

Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y . Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res. 2005; 65(3):999-1006. View

10.

Gorski D, Beckett M, Jaskowiak N, Calvin D, Mauceri H, Salloum R . Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999; 59(14):3374-8. View

11.

Pluderi M, Lucini V, Caronzolo D, Pannacci M, Costa F, Carrabba G . Long-term inhibition of glioma growth by systemic administration of human PEX. J Neurosurg Sci. 2003; 47(2):69-78. View

12.

Maia Jr A, Malheiros S, da Rocha A, da Silva C, Gabbai A, Ferraz F . MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol. 2005; 26(4):777-83. PMC: 7977110. View

13.

Hjelmeland M, Hjelmeland A, Sathornsumetee S, Reese E, Herbstreith M, Laping N . SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther. 2004; 3(6):737-45. View

14.

Ciafre S, Barillari G, Bongiorno-Borbone L, Wannenes F, Izquierdo M, Farace M . A tricistronic retroviral vector expressing natural antiangiogenic factors inhibits angiogenesis in vitro, but is not able to block tumor progression in vivo. Gene Ther. 2002; 9(4):297-302. DOI: 10.1038/sj.gt.3301652. View

15.

Zagzag D, Nomura M, Friedlander D, Blanco C, Gagner J, Nomura N . Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol. 2003; 196(2):394-402. DOI: 10.1002/jcp.10306. View

16.

Yung Y, Cheshier S, Santarelli J, Huang Z, Wagers A, Weissman I . Incorporation of naive bone marrow derived cells into the vascular architecture of brain tumor. Microcirculation. 2005; 11(8):699-708. DOI: 10.1080/10739680490521005. View

17.

Mentlein R, Eichler O, Forstreuter F, Held-Feindt J . Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer. 2001; 92(4):545-50. DOI: 10.1002/ijc.1223. View

18.

Khodarev N, Yu J, Labay E, Darga T, Brown C, Mauceri H . Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci. 2003; 116(Pt 6):1013-22. DOI: 10.1242/jcs.00281. View

19.

Machein M, Renninger S, de Lima-Hahn E, Plate K . Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol. 2003; 13(4):582-97. PMC: 8095860. DOI: 10.1111/j.1750-3639.2003.tb00487.x. View

20.

Sharma S, Sharma M, Sarkar C . Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology. 2005; 46(5):481-9. DOI: 10.1111/j.1365-2559.2005.02142.x. View